HHS reserves more vaccine manufacturing capacity; vaccine candidate enters late-stage trial

Jul 28, 2020 - 02:56 PM
hhs-health-and-human-services-seal

The Department of Health and Human Services’ Biomedical Advanced Research and Development Authority yesterday issued a $265 million task order reserving vaccine manufacturing capacity through December 2021 at an advanced manufacturing center in Texas.

The Center for Innovation in Advanced Development and Manufacturing, a public-private partnership between BARDA and the Texas A&M University System, manufactures medical countermeasures to respond to public health emergencies.

The order also will allow FUJIFILM Diosynth Biotechnologies to expand its manufacturing capacity at the center, the second in the nation to receive BARDA funding to reserve and expand COVID-19 vaccine manufacturing capacity as part of HHS’ Operation Warp Speed.

"To ensure we have the needed capacity, we are engaging domestic centers for advanced manufacturing that HHS has helped build in recent years,” said HHS Secretary Alex Azar. “Securing more manufacturing capacity here in America will help get a vaccine to Americans without a day wasted and prepare our nation for future emergencies."

 

In other news yesterday, Pfizer and BioNTech launched a global Phase 2/3 study to evaluate the safety and efficacy of a COVID-19 vaccine candidate in up to 30,000 people.

Related News Articles

Blog
RAND 5.0 – The Health Policy Equivalent of Groundhog Day
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
NASEM releases evidence review on COVID-19 vaccine safety
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
FDA approves combo test for flu, COVID-19; alerts providers to medical device risks 
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
CDC recommends additional dose of updated COVID-19 vaccine for older adults
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
FDA: Paxlovid no longer labeled for emergency use after March 8
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…